Document is current
Any future updates will be listed below
-
Authors
Mastrantoni, Luca https://orcid.org/0000-0003-1853-4927
Garufi, Giovanna https://orcid.org/0009-0001-1800-2122
Giordano, Giulia
Maliziola, Noemi
Di Monte, Elena
Arcuri, Giorgia
Frescura, Valentina
Rotondi, Angelachiara
Orlandi, Armando https://orcid.org/0000-0001-5253-4678
Carbognin, Luisa
Palazzo, Antonella
Miglietta, Federica
Pontolillo, Letizia
Fabi, Alessandra https://orcid.org/0000-0002-0758-8033
Gerratana, Lorenzo
Pannunzio, Sergio
Paris, Ida https://orcid.org/0000-0002-7445-3366
Pilotto, Sara https://orcid.org/0000-0003-2229-4874
Marazzi, Fabio
Franco, Antonio
Franceschini, Gianluca https://orcid.org/0000-0002-2950-3395
Dieci, Maria Vittoria https://orcid.org/0000-0002-3967-9861
Mazzeo, Roberta
Puglisi, Fabio https://orcid.org/0000-0003-0573-4938
Guarneri, Valentina https://orcid.org/0000-0002-2375-8397
Milella, Michele
Scambia, Giovanni
Giannarelli, Diana
Tortora, Giampaolo https://orcid.org/0000-0002-1378-4962
Bria, Emilio
- License Information
-
More Information
Article History
Received: 9 February 2024
Accepted: 28 January 2025
First Online: 5 February 2025
Competing interests
: AO has declared consulting fees/advisory role for Novartis, Roche, Eli-Lilly, Amgen, Daiichi Sankyo, travel and accommodation by Daiichi Sankyo, Novartis, Roche, Pfizer. AP has declared consulting fees/advisory role for Amgen, MSD, Novartis, travel and accommodation by Pfizer. LC is supported by Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC) under My First AIRC Grant (MFAG) No. MFAG25149. AF has declared consulting fees/advisory role for Astra Zeneca, Daiichi Sankyo, Eisai, Eli-Lilly. Epionpharma, exact science, MSD, Novartis, Pierre Fabre, Roche, Seagen. GT is supported by funds of Ministero della Salute (Ricerca Corrente 2022). EB is supported by Institutional funds of Università Cattolica del Sacro Cuore (UCSC-projects D1), by the AIRC under Investigator Grant (IG) No. IG20583 and the Italian Ministry of Health “Ricerca Corrente” 2024. EB received speakers’ and travels’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche. EB received institutional research grants from Astra-Zeneca, Roche. All other authors declare no financial or non-financial competing interests.
